40051-30-7 Usage
Chemical class
Phenothiazine
Molecular structure
10-(3-chloropropyl)-2-(methylsulphonyl)-10H-phenothiazine
Primary use
Antipsychotic medication
Specific application
Treatment of schizophrenia and other psychotic disorders
Pharmacological activity
Dopamine receptor antagonism
Mechanism of action
3-chloropropyl and methylsulphonyl functional groups
Potential application
Anti-cancer properties
Side effects
Present
Usage recommendation
Under the supervision of a healthcare professional
Check Digit Verification of cas no
The CAS Registry Mumber 40051-30-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,0,0,5 and 1 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 40051-30:
(7*4)+(6*0)+(5*0)+(4*5)+(3*1)+(2*3)+(1*0)=57
57 % 10 = 7
So 40051-30-7 is a valid CAS Registry Number.
InChI:InChI=1/C16H16ClNO2S2/c1-22(19,20)12-7-8-16-14(11-12)18(10-4-9-17)13-5-2-3-6-15(13)21-16/h2-3,5-8,11H,4,9-10H2,1H3
40051-30-7Relevant articles and documents
A Simple and Commercially Viable Process for Improved Yields of Metopimazine, a Dopamine D2-Receptor Antagonist
Karicherla, Venumanikanta,Phani, Kumar,Bodireddy, Mohan Reddy,Prashanth, Kumar Babu,Gajula, Madhusudana Rao,Pramod, Kumar
, p. 720 - 731 (2017/05/29)
An efficient, practical, and commercially viable manufacturing process was developed with ≥99.7% purity and 31% overall yield (including four chemical reactions and one recrystallization) for an active pharmaceutical ingredient, called Metopimazine (1), an antiemetic drug used to prevent emesis during chemotherapy. The development of two in situ, one-pot methods in the present synthetic route helped to improve the overall yield of 1 (31%) compared with earlier reports (15%). For the first time, characterization data of API (1), intermediates, and also possible impurities are presented. The key process issues and challenges were addressed effectively and achieved successfully.
